'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer

被引：6

作者：

Voskoboynik, Mark ^{[1
,2
]}

Staffurth, John ^{[3
]}

Malik, Zafar ^{[4
]}

Sweeney, Christopher ^{[5
,6
]}

Chowdhury, Simon ^{[1
,2
]}

机构：

[1] Guys Hosp, Dept Med Oncol, London SE1 9RT, England

[2] Sarah Cannon Res Inst UK, London, England

[3] Cardiff Univ, Inst Canc & Genet, Velindre Canc Ctr, Cardiff, S Glam, Wales

[4] Clatterbridge Canc Ctr, Bebington, Wirral, England

[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[6] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 11期

关键词：

CHAARTED; docetaxel; hormone sensitive; metastatic prostate cancer; Sweeney; MITOXANTRONE PLUS PREDNISONE; INCREASED SURVIVAL; OPEN-LABEL; CHEMOTHERAPY; ABIRATERONE; ENZALUTAMIDE; PHASE-3; TRIAL;

D O I：

10.1586/14737140.2014.971112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer. © Informa UK, Ltd.

引用

页码：1253 / 1256

页数：4

共 50 条

[31] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, Christopher J.
Chen, Yu-Hui
Carducci, Michael
Liu, Glenn
Jarrard, David F.
Eisenberger, Mario
Wong, Yu-Ning
Hahn, Noah
Kohli, Manish
Cooney, Matthew M.
Dreicer, Robert
Vogelzang, Nicholas J.
Picus, Joel
Shevrin, Daniel
Hussain, Maha
Garcia, Jorge A.
DiPaola, Robert S.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 737 - 746
[32] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Arnold Lee
Targeted Oncology, 2023, 18 : 793 - 800
[33] Optimal treatment for metastatic hormone-sensitive prostate cancer
Omlin, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
[34] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Lee, Arnold
TARGETED ONCOLOGY, 2023, 18 (05) : 793 - 800
[35] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
Li, Hengping
Zhang, Mao
Wang, Xiangrong
Liu, Yang
Li, Xuanpeng
FRONTIERS IN ONCOLOGY, 2022, 12
[36] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith, Matthew R.
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Kopyltsov, Evgeny
Park, Chandler H.
Alekseev, Boris
Montesa-Pino, Alvaro
Ye, Dingwei
Parnis, Francis
Cruz, Felipe
Tammela, Teuvo L. J.
Suzuki, Hiroyoshi
Utriainen, Tapio
Fu, Cheng
Uemura, Motohide
Mendez-Vidal, Maria J.
Maughan, Benjamin L.
Joensuu, Heikki
Thiele, Silke
Li, Rui
Kuss, Iris
Tombal, Bertrand
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142
[37] Systemic therapy in metastatic hormone-sensitive prostate cancer
McDonald, Jodie
O'Brien, Jonathan
Kostos, Louise
Lawrentschuk, Nathan
Azad, Arun A.
Murphy, Declan
Chen, Kenneth
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2022, 16 (04) : 234 - 239
[38] Treatment options for metastatic hormone-sensitive prostate cancer
Kostos, Louise
Murphy, Declan G.
LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
[39] Hormone-sensitive prostate cancer
Ohlmann, Carsten
UROLOGIE, 2023, 62 (04): : 345 - 346
[40] Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting
Puente, Javier
Grande, Enrique
Medina, Ana
Maroto, Pablo
Lainez, Nuria
Angel Arranz, Jose
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (05) : 307 - 318

← 1 2 3 4 5 →